Erratum: Expression of Concern: Modeling the Interaction between Quinolinate and the Receptor for Advanced Glycation End Products (RAGE): Relevance for Early Neuropathological Processes (PLoS ONE (2015) 10: 3 (e0120221) DOI: 10.1371/journal.pone.0120221);Modeling the interaction between quinolinate and the receptor for advanced glycation end products (RAGE): Relevance for early neuropathological processes

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Serratos, Iris N ^a,b   Castellanos, Pilar ^a   Pastor, Nina ^c   Millán Pacheco, César ^d   Rembao, Daniel ^e   Pérez Montfort, Ruy ^f   Cabrera, Nallely ^f   Reyes Espinosa, Francisco ^a   Díaz Garrido, Paulina ^b   López Macay, Ambar ^b   Martínez Flores, Karina ^b   López Reyes, Alberto ^b   Sánchez García, Aurora ^e   Cuevas, Elvis ^g   Santamaria, Abel ^b  

^a DEPARTAMENTO DE QUÍMICA   (Mexico)

^b HOSPITAL GENERAL DE MÉXICO   (Mexico)

^c UNIVERSIDAD AUTÓNOMA DEL ESTADO DE MORELOS   (Mexico)

^d INSTITUTO DE CIENCIAS FÍSICAS   (Mexico)

^e NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

^f INSTITUTO DE FISIOLOGÍA CELULAR   (Mexico)

^g NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; DIMER; HOMODIMER; QUINOLINIC ACID; S ALLYLCYSTEINE; AGER PROTEIN, RAT; PROTEIN BINDING;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CHEMICAL STRUCTURE; CONTROLLED STUDY; CORPUS STRIATUM; FLUORESCENCE ANALYSIS; IMAGE PROCESSING; IMMUNOBLOTTING; IMMUNOREACTIVITY; IN VITRO STUDY; MALE; MOLECULAR DOCKING; MOLECULAR MODEL; MOLECULAR RECOGNITION; NERVE CELL LESION; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; OLIGOMERIZATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; RECEPTOR BINDING; TISSUE DISTRIBUTION; ANIMAL; BRAIN; CHEMISTRY; DEGENERATIVE DISEASE; METABOLISM; OXIDATIVE STRESS; PATHOLOGY; PHYSIOLOGY; WISTAR RAT;

RATTUS;

ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; ANIMALS; BRAIN; MALE; MOLECULAR DOCKING SIMULATION; NEURODEGENERATIVE DISEASES; OXIDATIVE STRESS; PROTEIN BINDING; QUINOLINIC ACID; RATS, WISTAR;

EID: 84924371085     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0281905     Document Type: Erratum

References (74)

1. Olney JW. Excitotoxicity: an overview. Can Dis Wkly Rep Rapp Hebd Mal Au Can 1990; 16 Suppl: 1E: 47-57; discussion 57-58.
2. Zádori D, Klivényi P, Szalárdy L, Fülöp F, Toldi J, Vécsei L. Mitochondrial disturbances, excitotoxicity, neuroinflammation and kynurenines: novel therapeutic strategies for neurodegenerative disorders. J Neurol Sci. 2012; 322: 187-191. doi: 10.1016/j.jns.2012.06.004 PMID: 22749004
3. Essa MM, Braidy N, Vijayan KR, Subash S, Guillemin GJ. Excitotoxicity in the pathogenesis of autism. Neurotox Res. 2013; 23: 393-400. doi: 10.1007/s12640-012-9354-3 PMID: 23065398
4. Stone TW, Mackay GM, Forrest CM, Clark CJ, Darlington LG. Tryptophan metabolites and brain disorders. Clin Chem Lab Med CCLM FESCC. 2003; 41: 852-859. PMID: 12940508
5. Tan L, Yu JT, Tan L. The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations. J Neurol Sci. 2012; 323: 1-8. doi: 10.1016/j.jns.2012.08.005 PMID: 22939820
6. Pérez-De La Cruz V, Königsberg M, Santamaría A. Kynurenine pathway and disease: an overview. CNS Neurol Disord Drug Targets. 2007; 6: 398-410. PMID: 18220779
7. Schwarcz R, Bruno JP, Muchowski PJ, Wu H- Q. Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci. 2012; 13: 465-477. doi: 10.1038/nrn3257 PMID: 22678511
8. Schwarcz R, Foster AC, French ED, Whetsell WO, Köhler C. Excitotoxic models for neurodegenerative disorders. Life Sci 1984; 35: 19-32. PMID: 6234446
9. Pérez-De La Cruz V, Carrillo-Mora P, Santamaría A. Quinolinic Acid, an endogenous molecule combining excitotoxicity, oxidative stress and other toxic mechanisms. Int J Tryptophan Res 2012; 5: 1-8. doi: 10.4137/IJTR.S8158 PMID: 22408367
10. Cuevas E, Lantz S, Newport G, Divine B, Wu Q, Paule MG, et al. On the early toxic effect of quinolinic acid: involvement of RAGE. Neurosci Lett. 2010; 474: 74-78. doi: 10.1016/j.neulet.2010.03.007 PMID: 20223279
11. Ramasamy R, Vannucci SJ, Yan SSD, Herold K, Yan SF, Schmidt AM. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology. 2005; 15: 16R-28R. PMID: 15764591
12. Yan SF, Yan SD, Ramasamy R, Schmidt AM. Tempering the wrath of RAGE: an emerging therapeutic strategy against diabetic complications, neurodegeneration, and inflammation. Ann Med. 2009; 41: 408-422. doi: 10.1080/07853890902806576 PMID: 19322705
13. Chuah YK, Basir R, Talib H, Tie TH, Nordin N. Receptor for advanced glycation end products and its involvement in inflammatory diseases. Int J Inflamm. 2013: 403460. doi: 10.1155/2013/403460 PMID: 24102034
14. Bierhaus A, Nawroth PP. Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications. Diabetologia 2009; 52: 2251-2263. doi: 10.1007/s00125-009-1458-9 PMID: 19636529
15. Todorova J, Pasheva E. High mobility group B1 protein interacts with its receptor RAGE in tumor cells but not in normal tissues. Oncol Lett. 2012; 3: 214-218. PMID: 22740883
16. Vicente Miranda H, Outeiro TF. The sour side of neurodegenerative disorders: the effects of protein glycation. J Pathol. 2010; 221: 13-25. doi: 10.1002/path.2682 PMID: 20186922
17. Sparvero LJ, Asafu-Adjei D, Kang R, Tang D, Amin N, Rutledge R, et al. RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. J Transl Med. 2009; 7: 17. doi: 10.1186/1479-5876-7-17 PMID: 19292913
18. Mueller GA, Maleki SJ, Johnson K, Hurlburt BK, Cheng H, Ruan S, et al. Identification of Maillard reaction products on peanut allergens that influence binding to the receptor for advanced glycation end products. Allergy. 2013; 68: 1546-1554. doi: 10.1111/all.12261 PMID: 24266677
19. Matsumoto S, Yoshida T, Murata H, Harada S, Fujita N, Nakamura S, et al. Solution structure of the var-iable-type domain of the receptor for advanced glycation end products: new insight into AGE-RAGE interaction. Biochemistry (Mosc). 2008; 47: 12299-12311.
20. Gospodarska E, Kupniewska-Kozak A, Goch G, Dadlez M. Binding studies of truncated variants of the Aβ peptide to the V-domain of the RAGE receptor reveal Aβ residues responsible for binding. Biochim Biophys Acta. 2011; 1814: 592- 609. doi: 10.1016/j.bbapap.2011.02.011 PMID: 21354340
21. Chaney MO, Stine WB, Kokjohn TA, Kuo Y- M, Esh C, Rahman A, et al. RAGE and amyloid beta interactions: atomic force microscopy and molecular modeling. Biochim Biophys Acta. 2005; 1741: 199-205. PMID: 15882940
22. Chen RC, Yi PP, Zhou RR, Xiao MF, Huang ZB, Tang DL, et al. The role of HMGB1-RAGE axis in migration and invasion of hepatocellular carcinoma cell lines. Mol Cell Biochem. 2014; 390: 271-280. doi: 10.1007/s11010-014-1978-6 PMID: 24510323
23. Tian J, Avalos AM, Mao SY, Chen B, Senthil K, Wu H, et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol. 2007; 8: 487-496. PMID: 17417641
24. Kang R, Tang D, Schapiro NE, Loux T, Livesey KM, Billiar TR, et al. The HMGB1/RAGE inflammatory pathway promotes pancreatic tumor growth by regulating mitochondrial bioenergetics. Oncogene. 2014; 33: 567-577. doi: 10.1038/onc.2012.631 PMID: 23318458
25. Ostendorp T, Leclerc E, Galichet A, Koch M, Demling N, Weigle B, et al. Structural and functional insights into RAGE activation by multimeric S100B. EMBO J. 2007; 26: 3868-3878. PMID: 17660747
26. Koch M, Chitayat S, Dattilo BM, Schiefner A, Diez J, Chazin WJ, et al. Structural basis for ligand recognition and activation of RAGE. Struct Lond Engl 2010; 18: 1342-1352.
27. Leclerc E, Sturchler E, Vetter SW. The S100B/RAGE Axis in Alzheimer's disease. Cardiovasc Psychiatry Neurol. 2010; 539581. doi: 10.1155/2010/539581 PMID: 20672051
28. Park H, Adsit FG, Boyington JC. The 1.5 Å crystal structure of human receptor for advanced glycation endproducts (RAGE) ectodomains reveals unique features determining ligand binding. J Biol Chem. 2010; 285: 40762-40770. doi: 10.1074/jbc.M110.169276 PMID: 20943659
29. Lee D, Lee KH, Park H, Kim SH, Jin T, et al. The effect of soluble RAGE on inhibition of angiotensin IImediated atherosclerosis in apolipoprotein E deficient mice. PLoS ONE. 2013; 8: e69669. doi: 10. 1371/journal.pone.0069669 PMID: 23936343
30. Yang WI, Lee D, Lee DL, Hong SY, Lee SH, Kang SM, et al. Blocking the receptor for advanced glycation end product activation attenuates autoimmune myocarditis. Circ J Off J Jpn Circ Soc. 2014; 78: 1197-1205.
31. Yatime L, Andersen GR. Structural insights into the oligomerization mode of the human receptor for advanced glycation end-products. FEBS J. 2013; 280: 6556-6568. doi: 10.1111/febs.12556 PMID: 24119142
32. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et al. The Protein Data Bank. Nucleic Acids Res. 2000; 28: 235-242. PMID: 10592235
33. Xu D, Young JH, Krahn JM, Song D, Corbett KD, Chazin WJ, et al. Stable RAGE-heparan sulfate complexes are essential for signal transduction. ACS Chem Biol. 2013; 8: 1611-1620. doi: 10.1021/ cb4001553 PMID: 23679870
34. Sirois CM, Jin T, Miller AL, Bertheloot D, Nakamura H, Horvath G, et al. RAGE is a nucleic acid receptor that promotes inflammatory responses to DNA. J Exp Med. 2013; 210: 2447-2463. doi: 10.1084/jem. 20120201 PMID: 24081950
35. Xue J, Rai V, Singer D, Chabierski S, Xie J, Reverdatto S, et al. Advanced glycation end product recognition by the receptor for AGEs. Struct Lond Engl. 2011; 19: 722-732.
36. Rai V, Maldonado AY, Burz DS, Reverdatto S, Yan SF, Schmidt AM, et al. Signal transduction in receptor for advanced glycation end products (RAGE): solution structure of C-terminal rage (ctRAGE) and its binding to mDia1. J Biol Chem. 2012; 287: 5133-5144. doi: 10.1074/jbc.M111.277731 PMID: 22194616
37. Yatime L, Andersen GR. The specificity of DNA recognition by the RAGE receptor. J Exp Med. 2014; 211: 749-750. doi: 10.1084/jem.20132526 PMID: 24778420
38. Xue J, Ray R, Singer D, Böhme D, Burz DS, Rai V, et al. The receptor for advanced glycation end products (RAGE) specifically recognizes methylglyoxal-derived AGEs. Biochemistry (Mosc). 2014; 53: 3327-3335. doi: 10.1021/bi500046t PMID: 24824951
39. Tenorio-López FA, Valle-Mondragón L del, Martínez-Lazcano JC, Sánchez-Mendoza A, Ríos C, Paste-lín-Hernández G, et al. CZE determination of quinolinic acid in rat brain tissue and plasma. chromatographia 2007; 65: 725-731.
40. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates: Hard Cover Edition. Academic Press. 2007; 451 p.
41. Gómez-Quiroz LE, Factor VM, Kaposi-Novak P, Coulouarn C, Conner EA, Thorgeirsson SS. Hepato-cyte-specific c-Met deletion disrupts redox homeostasis and sensitizes to Fas-mediated apoptosis. J Biol Chem. 2008; 283: 14581-14589. doi: 10.1074/jbc.M707733200 PMID: 18348981
42. González RC, Woods RE. Digital Image Processing. 3 edition. Upper Saddle River, N.J: Prentice Hall. 2007; 976 p.
43. MATLAB. MATLAB. Natick, Massachusetts: The MathWorks Inc. 2010.
44. Grimsley GR, Pace CN. Spectrophotometric determination of protein concentration. Curr Protoc Protein Sci Editor Board John E Coligan Al Chapter 3: Unit 3.1. 2004.
45. Sánchez-Pozo A, Lupiánez JA, Gil A, Sánchez-Medina F. A sensitive method for determining quinolinic acid in animal tissues. Anal Biochem. 1982; 127: 159-163. PMID: 7165082
46. Levine RL, Federici MM. Quantitation of aromatic residues in proteins: model compounds for secondderivative spectroscopy. Biochemistry (Mosc). 1982; 21: 2600-2606.
47. González-Mondragón E, Zubillaga RA, Saavedra E, Chánez-Cárdenas ME, Pérez-Montfort R, Hernán-dez-Arana A. Conserved cysteine 126 in triosephosphate isomerase is required not for enzymatic activity but for proper folding and stability. Biochemistry (Mosc). 2004; 43: 3255-3263. PMID: 15023076
48. Serratos IN, Pérez-Hernández G, Garza-Ramos G, Hernández-Arana A, González-Mondragón E, Zubillaga RA. Binding thermodynamics of phosphorylated inhibitors to triosephosphate isomerase and the contribution of electrostatic interactions. J Mol Biol. 2011; 405: 158-172. doi: 10.1016/j.jmb.2010. 10.018 PMID: 20970429
49. Roy A, Kucukural A, Zhang Y. I-TASSER: a unified platform for automated protein structure and function prediction. Nat Protoc. 2010; 5: 725-738. doi: 10.1038/nprot.2010.5 PMID: 20360767
50. Zhang Y. I-TASSER server for protein 3D structure prediction. BMC Bioinformatics. 2008; 9: 40. doi: 10.1186/1471-2105-9-40 PMID: 18215316
51. Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, Villa E, et al. Scalable molecular dynamics with NAMD. J Comput Chem. 2005; 26: 1781-1802. PMID: 16222654
52. 2 Dihedral Angles. J Chem Theory Comput. 2012; 8: 3257-3273. PMID: 23341755
53. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al. UCSF Chimera-A visualization system for exploratory research and analysis. J Comput Chem. 2004; 25: 1605-1612. PMID: 15264254
54. Brooks BR, Brooks CL, Mackerell AD, Nilsson L, Petrella RJ, Roux B, et al. CHARMM: the biomolecular simulation program. J Comput Chem. 2009; 30: 1545-1614. doi: 10.1002/jcc.21287 PMID: 19444816
55. Trott O, Olson AJ. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010; 31: 455-461. doi: 10.1002/ jcc.21334 PMID: 19499576
56. Silva-Adaya D, Pérez-De La Cruz V, Herrera-Mundo MN, Mendoza-Macedo K, Villeda-Hernández J, Villeda-Hernández J, et al. Excitotoxic damage, disrupted energy metabolism, and oxidative stress in the rat brain: antioxidant and neuroprotective effects of L-carnitine. J Neurochem. 2008; 105: 677-689. doi: 10.1111/j.1471-4159.2007.05174.x PMID: 18194214
57. Velázquez-Campoy A, Ohtaka H, Nezami A, Muzammil S, Freire E. Isothermal titration calorimetry. Curr Protoc Cell Biol Editor Board Juan Bonifacino Al Chapter. 2004; 17: Unit 17.8.
58. Lee M- C, Ting KK, Adams S, Brew BJ, Chung R, Guillermin G. Characterisation of the expression of NMDA receptors in human astrocytes. PLoS ONE 2010; 5: e14123. doi: 10.1371/journal.pone. 0014123 PMID: 21152063
59. Bello Z, Grubmeyer C. Roles for Cationic Residues at the Quinolinic Acid Binding Site of Quinolinate Phosphoribosyltransferase. Biochemistry (Mosc). 2010; 49: 1388-1395.
60. Malik SS, Patterson DN, Ncube Z, Toth EA. The crystal structure of human quinolinic acid phosphoribosyltransferase in complex with its inhibitor phthalic acid. Proteins Struct Funct Bioinforma 2014; 82: 405-414. doi: 10.1002/prot.24406 PMID: 24038671
61. Borgonovo J, Seltzer A, Sosa MA. Acute intrastriatal administration of quinolinic acid affects the expression of the coat protein AP-2 and its interaction with membranes. J Neural Transm. 2009; 116: 1201-1208. doi: 10.1007/s00702-009-0262-5 PMID: 19597933
62. Bierhaus A, Schiekofer S, Schwaninger M, Andrassy M, Humpert PM, Chen J, et al. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes. 2001; 50: 2792-2808. PMID: 11723063
63. Santamaría A, Salvatierra-Sánchez R, Vázquez-Román B, Santiago-López D, Villeda-Hernández J, Galván-Arzate S, et al. Protective effects of the antioxidant selenium on quinolinic acid-induced neurotoxicity in rats: in vitro and in vivo studies. J Neurochem. 2003; 86: 479-488. PMID: 12871589
64. Haas SJ- P, Ahrens A, Petrov S, Schmitt O, Wree A. Quinolinic acid lesions of the caudate putamen in the rat lead to a local increase of ciliary neurotrophic factor. J Anat. 2004; 204: 271-281. PMID: 15061753
65. Feng Q, Ma Y, Mu S, Wu J, Chen S, Ouyang L, et al. Specific reactions of different striatal neuron types in morphology induced by quinolinic acid in rats. PLoS ONE. 2014; 9: e91512. doi: 10.1371/journal. pone.0091512 PMID: 24632560
66. Raucci A, Cugusi S, Antonelli A, Barabino SM, Monti L, Bierhaus A, et al. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membranebound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J. 2008; 22: 3716-3727. doi: 10.1096/fj.08-109033 PMID: 18603587
67. Loeser RF, Yammani RR, Carlson CS, Chen H, Cole A, Im HJ, et al. Articular chondrocytes express the receptor for advanced glycation end products: Potential role in osteoarthritis. Arthritis Rheum. 2005; 52: 2376-2385. PMID: 16052547
68. Pérez-Severiano F, Rodríguez-Pérez M, Pedraza-Chaverrí J, Maldonado PD, Medina-Campos ON, Ortiz-Plata A, et al. S-Allylcysteine, a garlic-derived antioxidant, ameliorates quinolinic acid-induced neurotoxicity and oxidative damage in rats. Neurochem Int. 2004; 45: 1175-1183. PMID: 15380627
69. De Bittencourt Pasquali MA, Gelain DP, Zeidán-Chuliá F, Pires AS, Gasparotto J, Terra SR, et al. Vitamin A (retinol) downregulates the receptor for advanced glycation endproducts (RAGE) by oxidant-dependent activation of p38 MAPK and NF-kB in human lung cancer A549 cells. Cell Signal. 2013; 25: 939-954. doi: 10.1016/j.cellsig.2013.01.013 PMID: 23333461
70. Reverdatto S, Rai V, Xue J, Burz DS, Schmidt AM, Shekhtman A. Combinatorial library of improved peptide aptamers, CLIPs to inhibit RAGE signal transduction in mammalian cells. PloS One. 2013; 8: e65180. doi: 10.1371/journal.pone.0065180 PMID: 23785412
71. Wilton R, Yousef MA, Saxena P, Szpunar M, Stevens FJ. Expression and purification of recombinant human receptor for advanced glycation endproducts in Escherichia coli. Protein Expr Purif. 2006; 47: 25-35. PMID: 16510295
72. Sitkiewicz E, Tarnowski K, Poznański J, Kulma M, Dadlez M. Oligomerization interface of RAGE receptor revealed by MS-monitored hydrogen deuterium exchange. PloS One. 2013; 8: e76353. doi: 10. 1371/journal.pone.0076353 PMID: 24098480
73. Laskowski RA, Swindells MB. LigPlot+: Multiple Ligand-Protein Interaction Diagrams for Drug Discovery. J Chem Inf Model. 2011; 51: 2778-2786. doi: 10.1021/ci200227u PMID: 21919503
74. Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. J Mol Graph. 1996; 14: 33-38, 27-28. PMID: 8744570